Dr. Khan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Center Drive
Bethesda, MD 20892
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2017 - 2018
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2014 - 2017
- Yale School of MedicineClass of 2014
Certifications & Licensure
- DC State Medical License 2017 - 2024
- MD State Medical License 2022 - 2024
- NY State Medical License 2020 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Brea...Aditya Bardia, Komal Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis
Journal of Clinical Oncology. 2024-09-12 - 24 citationsTROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.Aditya Bardia, Komal Jhaveri, Kevin Kalinsky, Sonia Pernas, Junji Tsurutani
Future Oncology. 2024-03-01 - 2 citationsGenomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancersSabrina S. Khan, Thomas Karn, W. Fraser Symmans, Achim Rody, Volkmar Müller
Breast Cancer Research and Treatment. 2015-02-05
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: